logo

Exclusive Market Insight

& Scientific analysis

subscribe today
  • Exclusive Posts
  • Industry Newsletters
  • Clinical Trials
  • Possible Takeovers
  • Technology of the Week
  • Stock Table
  • Therapeutic Vaccines
  • Development-Stage Firms
  • Genomics
  • Prohost Picks
  • And much more...
Trick or TradeToday’s HighlightsProhost LettersNews & CommentsImpacting NewsContact
Login

Category: Today’s Highlights

Amgen, Rhythm Pharmaceuticals and an important story to know

Amgen Higher Dividends For those who invest in top-tier biotech firms for dividend payments, in addition to the firms’ continued growth, Amgen (AMGN) announced last Friday that its Board of Directors declared a  $1.45 per share dividend for the first quarter...

Read More

December 12, 2018

0

Bristol-Myers Squibb and bluebird bio Product Ide-Cel, Bb2121 and the FDA Refusal Letter. What Do We Expect?

Bristol-Myers Squibb and bluebird bio  Bristol-Myers Squibb ( BMY ) and bluebird bio ( BLUE ) received a Refusal to File letter from the United States FDA regarding the Biologics License Application ( BLA ), which was submitted in March...

Read More

May 13, 2020

0

Great biotech news in a bizarre market. Incyte has two consecutive good news

During the departed week, outstanding advancements and improvements in various clinical disciplines filled the media. What’s bad is that all the accomplishments could not bring joy to the deserving investors. The reason is the unpersuasive crazy market behavior. We believe...

Read More

December 17, 2018

0

Proteostasis: Its $100 million agreement with Genentech seems not enough to motivate investors to buy into the stock

Proteostasis (PTI) signed a worldwide, exclusive license agreement with Genentech  about licensing rights to potential therapeutic small molecule modulators of an undisclosed target within the proteostasis network . The agreement does not include cystic fibrosis (CF)  transmembrane conductance regulator (CFTR)...

Read More

December 18, 2018

0

Prohost greetings and opinions

We Wish You A Happy Spiritual Season and A Happy New Year 2019. We Hope that Peace of Mind, Serenity  and Optimistic Feelings Replace Unwarranted Pessimistic, False Impressions   That Have No Root in America’s Reality We Love You All...

Read More

December 24, 2018

0

Moderna: Pricing of a Public Offering of 17,600,000 Shares at $76.00 Per Share

Moderna Inc: A Public Offering Moderna ( MRNA ) announced the pricing of an underwritten public offering of 17,600,000 shares of common stock at a public offering price of $76.00 per share, before underwriting discounts and commissions. Moderna has also granted the...

Read More

May 19, 2020

0

Small firms developing improved CAR T immunotherapy products.

We have a few small clinical stage firms in the Prohost Portfolio  that were established with the goal of designing safer and more effective versions of the very promising CAR T immuno-oncology products . We intend to revisit these firms...

Read More

December 28, 2018

0

Gilead Sciences and Galapagos NV: Good News from Filgotinib in Ulcerative Colitis

Gilead Sciences and Galapagos NV Announce Good News from Filgotinib Trial Gilead Sciences ( GILD ) and Galapagos NV ( GLPG ) announced positive topline results from the SELECTION trial - a randomized, double-blind, placebo-controlled, Phase 2b/3 trial evaluating the...

Read More

May 21, 2020

0

Bristol-Myers to acquire Celgene. Was this move really a surprise?

Bristol-Myers Squibb (BMY)   will acquire Celgene (CELG)  i n a cash and stock transaction with an equity value of approximately $74 billion . Under the terms of the agreement: Celgene shareholders will receive 1.0 Bristol-Myers Squibb share and $50.00...

Read More

January 3, 2019

0

Why Loxo Oncology's and Sage Therapeutics' stocks staged a Rally today

Why Loxo Oncology and  Sage Therapeutics Have Occupied Today's Headline News LOXO Oncology Eli Lilly (LILY)  announced its intention to acquire Loxo Oncology (LOXO)   for around $8 billion in cash .  The offer translates to around $235 a share,...

Read More

January 7, 2019

0

  • Previous
  • 1
  • 2
  • ...
  • 88
  • 89
  • 90
  • ...
  • 172
  • 173
  • Next

Search ProhostBiotech

Popular Links

23andMe Holding Co (ME)Abbott Laboratories (ABT)AbbVie Inc (ABBV)AbCelleraAbeona Therapeutics (ABEO)Ablynx (ABLX)AbVitro IncAcadia (ACAD)Acceleron Pharma (XLRN)AcelRx Pharmaceuticals (ACRX).Acorda Therapeutics Inc (ACOR)Acumen Pharmaceuticals (ABOS)AdaptImmune Therapeutics (ADAP)Adaptive BiotechnologiesADC Therapeutics (ADCT)Adimab LLCAdvanced Micro Devices (AMD)Advaxis (ADXS)Adverum Biotechnologies (ADVM)Aerie Pharmaceuticals (AERI)AgenTus TherapeuticsAgenus (AGEN)AgeX Therapeutics (AGE)Agilent Technologies (A)Agilis Biotherapeutics IncAgios Pharmaceuticals (AGIO)AIM ImmunoTech (AIM)Aimmune Therapeutics (AIMT)Akari Therapeutics (AKTX)Akashi TherapeuticsAkcea Therapeutics (AKCA)Akebia Therapeutics Inc (AKBA)Akero Therapeutics (AKRO)Akous Inc (a wholly owned subsidiary of Eli Lilly Company)Alder BioPharmaceuticals (ALDR)Alexion Pharmaceuticals (ALXN)Alkermes (ALKS)Allergan Plc (AGN)Allogene TherapeuticsAllogene Therapeutics (ALLO)

Recent

AstraZeneca Product Fasenra Approved in the US for Eosinophilic Granulomatosis with Polyangiitis 

September 19, 2024

0

The U.S. FDA Approves Novartis' Kisqali® to Reduce the Risk of Recurrence in People with HR+/HER2- Early Breast Cancer

September 18, 2024

0

AstraZeneca’s Imfinzi + Imjudo Demonstrated Unprecedented Overall Survival in Advanced Liver Cancer

September 17, 2024

0

Halozyme Therapeutics Announced FDA Approval of Roche’s Tecentriq Hybreza with ENHANZE

September 13, 2024

0

Johnson & Johnson Product TREMFYA® Receives U.S. FDA Approval

September 12, 2024

0

Prohost Biotech – Exclusive Biotech Research Copyright © 2026.
Privacy Policy